Related Experiment Videos
Depression, hypertension, and serum dopamine-beta-hydroxylase activity
Psychosomatic Medicine
|March 1, 1978
Summary
Serum dopamine-beta-hydroxylase (DBH) activity is linked to depressive symptoms in outpatients. Elevated DBH activity correlated with higher depression scores, but not blood pressure. Certain medications also altered DBH levels.
Area of Science:
- Neuroscience
- Psychiatry
- Clinical Medicine
Background:
- Serum dopamine-beta-hydroxylase (DBH) is an enzyme involved in neurotransmitter synthesis.
- DBH activity has been implicated in various neurological and psychiatric conditions.
- Understanding DBH activity in relation to common health issues like depression and hypertension is clinically relevant.
Purpose of the Study:
- To investigate the association between serum dopamine-beta-hydroxylase (DBH) activity and depressive symptomatology.
- To examine the relationship between DBH activity and elevated diastolic blood pressure.
- To explore the impact of specific pharmacological agents on serum DBH activity.
Main Methods:
- Serum DBH activity was measured in 290 outpatients.
- Depressive symptomatology was assessed using the Zung Self-Rating Depression Scale (SDS).
- Elevated diastolic blood pressure was defined as >= 90 mm Hg.
Main Results:
- Elevated serum DBH activity was significantly associated with higher SDS scores (>= 60).
- No significant statistical association was found between DBH activity and diastolic blood pressure.
- Alpha-methyl-DOPA and minor tranquilizers were associated with significant alterations in serum DBH activity.
Conclusions:
- Serum DBH activity may serve as a biomarker for depressive symptomatology in outpatient settings.
- DBH activity does not appear to be directly associated with diastolic blood pressure in this cohort.
- Pharmacological interventions can influence serum DBH levels, warranting consideration in clinical practice.